Abstract
Portal vein thrombosis (PVT) is a relatively common event in patients with advanced-stage liver cirrhosis, even in patients with a compensated disease. Because of the protean clinical manifestation of PVT, ranging from massive variceal bleeding and mesenteric infarction to the complete absence of any symptom, it is mandatory to provide an early diagnosis and a prompt management. However, even if various treatments have been tested in clinical studies, most of them can be suitable only for a limited number of patients and anticoagulants are recognized as the gold standard, even if the debate about their use in PVT management in cirrhotic patients is still opened. In particular, “old” and “new” generations of anticoagulants have always been used carefully and, sometimes, with skepticism or diffidence in cirrhotic patients. In this review, we report the rationale of anticoagulants use in PVT cirrhotic patients management, analyzing the most accepted controversies and certainties, with a particular attention to their possible role as preemptive therapy.
Keywords: Anticoagulants, liver cirrhosis, portal vein thrombosis, coagulation system, vitamin k antagonists, warfarin, heparin, INR, bleeding, bowel ischemia, recanalization, pro-thormbotic disorders, portal vein thrombosis prevention, factor X inhibitors
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title: Anticoagulants in Cirrhotic Patients: Controversies and Certainties in PVT Management
Volume: 9 Issue: 3
Author(s): Francesca R. Ponziani, Maria A. Zocco, Annalisa Tortora, Giovanni Gasbarrini and Antonio Gasbarrini
Affiliation:
Keywords: Anticoagulants, liver cirrhosis, portal vein thrombosis, coagulation system, vitamin k antagonists, warfarin, heparin, INR, bleeding, bowel ischemia, recanalization, pro-thormbotic disorders, portal vein thrombosis prevention, factor X inhibitors
Abstract: Portal vein thrombosis (PVT) is a relatively common event in patients with advanced-stage liver cirrhosis, even in patients with a compensated disease. Because of the protean clinical manifestation of PVT, ranging from massive variceal bleeding and mesenteric infarction to the complete absence of any symptom, it is mandatory to provide an early diagnosis and a prompt management. However, even if various treatments have been tested in clinical studies, most of them can be suitable only for a limited number of patients and anticoagulants are recognized as the gold standard, even if the debate about their use in PVT management in cirrhotic patients is still opened. In particular, “old” and “new” generations of anticoagulants have always been used carefully and, sometimes, with skepticism or diffidence in cirrhotic patients. In this review, we report the rationale of anticoagulants use in PVT cirrhotic patients management, analyzing the most accepted controversies and certainties, with a particular attention to their possible role as preemptive therapy.
Export Options
About this article
Cite this article as:
R. Ponziani Francesca, A. Zocco Maria, Tortora Annalisa, Gasbarrini Giovanni and Gasbarrini Antonio, Anticoagulants in Cirrhotic Patients: Controversies and Certainties in PVT Management, Cardiovascular & Hematological Agents in Medicinal Chemistry 2011; 9 (3) . https://dx.doi.org/10.2174/187152511797037448
DOI https://dx.doi.org/10.2174/187152511797037448 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
Call for Papers in Thematic Issues
Medicinal Plants with Beneficial Properties on Diabetes and Hypertension
Diabetes and hypertension are real scourges of the 21st century. It is imperative to act in order to find innovative solutions to this problem. Taking medications such as hypoglycemic and antihypertensive drugs may aggravate certain underlying comorbidities, such as chronic kidney disease and cardiovascular disease. This significant drawback therefore requires ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
FK506: Anti-Inflammatory Properties
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Pleiotropic Effects of Nicotinic Acid: Beyond High Density Lipoprotein Cholesterol Elevation
Current Vascular Pharmacology Current Therapy in Sarcoidosis, the Role of Existing Drugs and Future Medicine
Inflammation & Allergy - Drug Targets (Discontinued) ATP-Sensitive Potassium Channel Openers and 2,3-Dimethyl-2-Butylamine Derivatives
Current Medicinal Chemistry Statins in Stroke Prevention: Present and Future
Current Pharmaceutical Design IPR and Technological Issues Regarding a Biopharmaceutical Formulation -Hemoglobin
Recent Patents on Biotechnology Globalization of Clinical Trials – Where are We Heading?
Current Clinical Pharmacology Statins and Inflammation in Cardiovascular Disease
Current Pharmaceutical Design Epidemiology, Prognosis and Prevention of Non-Traumatic Intracerebral Hemorrhage
Current Pharmaceutical Design Brain Angiotensinergic Regulation of the Immune System: Implications for Cardiovascular and Neuroendocrine Responses
Endocrine, Metabolic & Immune Disorders - Drug Targets Development of Anti-Atherosclerosis Therapy Based on the Inflammatory and Proliferative Aspects of the Disease
Current Pharmaceutical Design Carbon Monoxide and the Brain: Time to Rethink the Dogma
Current Pharmaceutical Design Cardiovascular Morbidity and Mortality in Obstructive Sleep Apnea
Current Pharmaceutical Design Editorial (Thematic Issue: Therapeutic Potential of microRNAs in Vascular Disease)
Current Vascular Pharmacology The Role of Hypoxia and Platelets in Air Travel-Related Venous Thromboembolism
Current Pharmaceutical Design Ezetimibe and Vascular Endothelial Function
Current Vascular Pharmacology Angiogenesis-regulating microRNAs and Ischemic Stroke
Current Vascular Pharmacology Melatonin as a Therapeutic Resource for Inflammatory Visual Diseases
Current Neuropharmacology Clinical Utility of the Ankle-Brachial Index and Toe Brachial Index in Patients with Diabetic Foot Ulcers
Current Diabetes Reviews Targeting Plasminogen Activator Inhibitor-1: Role in Cell Signaling and the Biology of Domain-Specific Knock-in Mice
Current Drug Targets